Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Novartis MS Pill Gilenya Rejected by U.K. Health-Cost Agency
Bloomberg
Wednesday, November 30, 2011 - 7:42pm
tags:
Novartis, MS, multiple sclerosis, Gilenya
Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity
Seeking Alpha
Wednesday, November 30, 2011 - 5:29pm
tags:
Krystexxa, Savient, gout
A Simple Plan (to Save US Pharma Manufacturing)
Pharm Exec
Wednesday, November 30, 2011 - 2:19pm
tags:
drug manufacturing
Hospira's production woes widespread, analyst says
Fierce Pharma
Wednesday, November 30, 2011 - 2:13pm
tags:
Hospira, drug manufacturing
Pfizer and Merck May Benefit From Spinoffs, Goldman Sachs Says
Bloomberg
Wednesday, November 30, 2011 - 2:10pm
tags:
Pfizer, Merck, spinoff
Two Top Biotech Plays With Safe Upside
Seeking Alpha
Wednesday, November 30, 2011 - 2:09pm
tags:
ImmunoCellular, glioblastoma multiforme, brain cancer, Bristol-Myers Squibb, Yervoy, melanoma
Why the Street Should Love Merck's Earnings
Motley Fool
Wednesday, November 30, 2011 - 11:51am
tags:
Merck, earnings
Rivals threaten to take wind from Watson’s generic Lipitor sales
Med City
Wednesday, November 30, 2011 - 11:31am
tags:
Watson, generics, Pfizer, Lipitor, Teva Pharmaceuticals, Ranbaxy
Pfizer After Lipitor to Push Mini-Blockbusters
Bloomberg
Wednesday, November 30, 2011 - 11:29am
tags:
Pfizer, generics, Lipitor
Why There Will Never Be Another Drug Like Lipitor
Forbes
Wednesday, November 30, 2011 - 11:28am
tags:
Pfizer, generics, statins, Lipitor
GSK shakes up R&D units during high-profile review
Fierce Biotech
Wednesday, November 30, 2011 - 10:50am
tags:
GSK, R&D
New Drug Approvals Make Or Break Biotechnology Stocks
Seeking Alpha
Wednesday, November 30, 2011 - 10:46am
tags:
Antares, Achillion, Pharmasset, Indenix, Inhibitex, ONYX Pharmaceuticals, Keryx
Every Biotech Is for Sale
Motley Fool
Wednesday, November 30, 2011 - 10:45am
tags:
ONYX Pharmaceuticals, Achillion, BioSante, Indenix, Inhibitex, GSK, Bristol-Myers Squibb, Amarin, Exelixis
Forget The Rumors: Why Pfizer Might Be Incentivized To Acquire Lpath Outright
Seeking Alpha
Wednesday, November 30, 2011 - 10:43am
tags:
Lpath, Pfizer, M&A, lipid signaling
Onyx' Cancer Drug on Right Track
Yahoo/Zacks.com
Wednesday, November 30, 2011 - 10:37am
tags:
ONYX Pharmaceuticals, Carfilzomib, Multiple Myeloma
Novartis’s Lucentis Fails to Win Backing in Final U.K. Guidance
Bloomberg Businessweek
Wednesday, November 30, 2011 - 9:30am
tags:
Novartis, Lucentis, UK, diabetic macular edema
Watson Pharma Confirms Launch Of Generic Lipitor
WSJ Online
Wednesday, November 30, 2011 - 9:23am
tags:
Watson, generics, Lipitor, Pfizer, statins
FDA pins approval on new formulation of Ambien
Fierce Drug Delivery
Wednesday, November 30, 2011 - 9:22am
tags:
FDA, insomnia, Ambien, Transcept, Purdue, Intermezzo
Biologic Drugs: A Fast Growing Industry In The Making
Seeking Alpha
Wednesday, November 30, 2011 - 9:13am
tags:
biologics, Abbott Laboratories, Biogen Idec, Impax, Sangamo BioSciences
Pfizer aims to keep one-third of Lipitor pie
Reuters
Wednesday, November 30, 2011 - 9:11am
tags:
Pfizer, Lipitor, generics, statins

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.